Abstract:Glioblastoma (GBM) is uniformly fatal with a 1-year median survival, despite best available treatment, including radiotherapy (RT). Impacts of prior RT on tumor recurrence are poorly understood but may increase tumor aggressiveness. Metabolic changes have been investigated in radiation-induced brain injury; however, the tumor-promoting effect following prior radiation is lacking. Since RT is vital to GBM management, we quantified tumor-promoting effects of prior RT on patient-derived intracranial GBM xenografts and characterized metabolic alterations associated with the protumorigenic microenvironment. Human xenografts (GBM143) were implanted into nude mice 24 hrs following 20 Gy cranial radiation vs. sham animals. Tumors in pre-radiated mice were more proliferative and more infiltrative, yielding faster mortality (p < 0.0001). Histologic evaluation of tumor associated macrophage/microglia (TAMs) revealed cells with a more fully activated ameboid morphology in pre-radiated animals. Microdialyzates from radiated brain at the margin of tumor infiltration contralateral to the site of implantation were analyzed by unsupervised liquid chromatography-mass spectrometry (LC-MS). In pre-radiated animals, metabolites known to be associated with tumor progression (i.e., modified nucleotides and polyols) were identified. Whole-tissue metabolomic analysis of pre-radiated brain microenvironment for metabolic alterations in a separate cohort of nude mice using 1H-NMR revealed a significant decrease in levels of antioxidants (glutathione (GSH) and ascorbate (ASC)), NAD+, Tricarboxylic acid cycle (TCA) intermediates, and rise in energy carriers (ATP, GTP). GSH and ASC showed highest Variable Importance on Projection prediction (VIPpred) (1.65) in Orthogonal Partial least square Discriminant Analysis (OPLS-DA); Ascorbate catabolism was identified by GC-MS. To assess longevity of radiation effects, we compared survival with implantation occurring 2 months vs. 24 hrs following radiation, finding worse survival in animals implanted at 2 months. These radiation-induced alterations are consistent with a chronic disease-like microenvironment characterized by reduced levels of antioxidants and NAD+, and elevated extracellular ATP and GTP serving as chemoattractants, promoting cell motility and vesicular secretion with decreased levels of GSH and ASC exacerbating oxidative stress. Taken together, these data suggest IR induces tumor-permissive changes in the microenvironment with metabolomic alterations that may facilitate tumor aggressiveness with important implications for recurrent glioblastoma. Harnessing these metabolomic insights may provide opportunities to attenuate RT-associated aggressiveness of recurrent GBM.

YM155 Decreases Radiation-Induced Invasion and Reverses Epithelial–mesenchymal Transition by Targeting STAT3 in Glioblastoma

Abstract 570: Radiation Resistance of Orthotopic Glioblastoma Xenografts is Mediated by Increasing CD133+ Cell Fraction, Mobilizing G0 Cells into G1 Phase, and Activating Self-Renewal and Mesenchymal Genes

Silencing of Survivin Using YM155 Inhibits Invasion and Suppresses Proliferation in Glioma Cells

Effects of Combined Radiosurgery and Temozolomide Therapy on Epidermal Growth Factor Receptor and Variant III in Glioblastoma Multiforme.

Resveratrol Suppresses Epithelial-Mesenchymal Transition in GBM by Regulating Smad-Dependent Signaling

Radioactive 125I seeds inhibit cell growth and epithelial-mesenchymal transition in human glioblastoma multiforme via a ROS-mediated signaling pathway

Combined EGFR and autophagy modulation impairs cell migration and enhances radiosensitivity in human glioblastoma cells

Radiation with STAT3 Blockade Triggers Dendritic Cell-T cell Interactions in the Glioma Microenvironment and Therapeutic Efficacy

TGF-β/Smads Signaling Affects Radiation Response and Prolongs Survival by Regulating DNA Repair Genes in Malignant Glioma.

MMP14 Contributes to HDAC Inhibition-Induced Radiosensitization of Glioblastoma

Suppression of autophagy augments the radiosensitizing effects of STAT3 inhibition on human glioma cells.

Combination Therapy with Gamma Knife Radiosurgery and Antisense EGFR for Malignant Glioma in Vitro and Orthotopic Xenografts.

Alteration of Dna Damage Signaling Pathway Profile in Radiation-Treated Glioblastoma Stem-Like Cells

Brain targeted biomimetic siRNA nanoparticles for drug resistance glioblastoma treatment

Targeting Stat3 Suppresses Growth of U251 Cell-Derived Tumours in Nude Mice

Radiation-induced YAP Activation Confers Glioma Radioresistance Via Promoting FGF2 Transcription and DNA Damage Repair

SMAD3 Silencing Enhances DNA Damage in Radiation Therapy by Interacting with MRE11-RAD50-NBS1 Complex in Glioma.

Kill two birds with one stone: Engineered exosome-mediated delivery of cholesterol modified YY1-siRNA enhances chemoradiotherapy sensitivity of glioblastoma

Radiation Induced Metabolic Alterations Associate With Tumor Aggressiveness and Poor Outcome in Glioblastoma

EGFRvIII Promotes the Proneural-Mesenchymal Transition of Glioblastoma Multiforme and Reduces Its Sensitivity to Temozolomide by Regulating the NF-?B/ALDH1A3 Axis

Myeloid cells coordinately induce glioma cell-intrinsic and cell-extrinsic pathways for chemoresistance via GP130 signaling